Systemic therapy of skin metastatic melanoma with BRAF gene mutation
Purpose of the study. To conduct a comparative analysis of the effectiveness of the use of mono‑mode immuno‑oncological and targeted drugs in the first line of therapy in patients with metastatic melanoma of the skin (SMM) in patients with BRAF mutation.Patients and methods. To achieve this goal, a...
Saved in:
| Main Authors: | Yu. S. Shakh-Paronyants, S. V. Cheporov, N. P. Shiryaev, A. V. Ukgarskiy, P. V. Nesterov, N. S. Korzina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2023-03-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/869 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01) -
Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01) -
The relationship of clinical and morphological parameters with the BRAF status of the tumor in patients with stage I skin melanoma
by: K. S. Titov, et al.
Published: (2024-09-01) -
Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01) -
Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition
by: Danielle G. Carvalho, et al.
Published: (2025-07-01)